1. Is it good clinical judgment or selection bias?

   • Maurie Markman

   Editor’s Commentary Pages: 377 - 378

2. Web alert

   News Pages: 379 - 380

3. Literature alert

   Abstract Pages: 381 - 383

4. Assessing the quality of clinical trials: Can it be done?

   • Charles L. Bennett
   • Jared R. Adams

   Clinical Trials Report Pages: 387 - 388

5. Acknowledgment of uncertainty: A fundamental means to ensure scientific and ethical validity in clinical research

   • Benjamin Djulbegovic

   OriginalPaper Pages: 389 - 395

6. Economic analysis of randomized, controlled trials

   • Gary H. Lyman

   OriginalPaper Pages: 396 - 403

7. Is cancer care best at high-volume providers?

   • Bruce E. Hillner

   OriginalPaper Pages: 404 - 409

8. Conflict of interest in industrysponsored economic evaluations: Real or imagined?

   • Marco Barbieri
   • Michael F. Drummond

   OriginalPaper Pages: 410 - 413

9. Immunotherapy for prostate cancer

   • Brian I. Rini
   • Eric J. Small

   OriginalPaper Pages: 418 - 423

10. The role of resection for patients with renal carcinoma

    • Robert C. Flanigan
    • Paul M. Yonover

    OriginalPaper Pages: 424 - 432

11. Allogeneic stem-cell transplantation in renal-cell carcinoma

    • Brandon M. Hayes-Lattin
    • Richard T. Maziarz
    • Tomasz M. Beer

    OriginalPaper Pages: 433 - 437

12. Gene therapy for prostate cancer

    • Jeffrey R. Gingrich
    • Ravi D. Chauhan
    • Mitchell S. Steiner

    OriginalPaper Pages: 438 - 447

13. Complementary and alternative medicine in prostate cancer

    • Judith S. Jacobson
    • Anitha P. Chetty

    OriginalPaper Pages: 448 - 452

14. Combination therapy in hormone-refractory prostate cancer

    • Daniel P. Petrylak

    Clinical Trials Report Pages: 453 - 453